VIRMA and ovarian cancer: According to risk score models, patients with ovarian cancer who had low VIRMA or high HNRNPA2B1 expression had prolonged half survival, and the constructed miRNA-m6A regulator (VIRMA, IGF2BP1, HNRNPA2B1)-target gene regulatory network could predict the prognosis of OC patients [71].